Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China and Boston, USA.

Our current therapeutic areas of interest include oncology, metabolic diseases and autoimmune diseases. By leveraging our industry-leading core strength in CARD (Computer Accelerated Rational Discovery)...

+Read More+

News & Events

View All
  • 22 June, 2021

    Regor’s discovery team published their Structural Biology work on the human glucagon-like peptide-1 receptor (GLP1R)

    +Read More+
  • 18 Feb, 2021

    Regor Therapeutics Announces Completion of $90 Million Series B Financing

    +Read More+
  • 30 Mar, 2020

    Regor Scientists Published Articles in Recent Issues of Cell Research, Science Advances and Nature Chemical Biology

    +Read More+

Core Technologies

CARD, Computer Accelerated Rational Discovery, is a powerful and proprietary technology platform

+Read More+


Initiated 3 IND enabling programs and 9 additional early stage programs

+Read More+

Career Opportunities

Accelerated Discovery. Breakthrough Medicines.

To serve patients around the world through innovative and clinically differentiated drugs

To accelerate portfolio delivery and value creation through enabling technology platforms

+Read More+

245 Main Street, Second Floor, Cambridge, MA 02142, USA 1206 Zhangjiang Rd, Building C, Pudong New District, Shanghai 201210, China